Keyphrases
Adalimumab
8%
Adjusted Odds Ratio
25%
Age-specific
8%
Alanine Aminotransferase
91%
Antibiotic Exposure
8%
Autoimmune Hepatitis
33%
Biological Treatment
100%
Children's Hospital
8%
Confidence Interval
25%
Disease Duration
8%
Elevated Liver Enzymes
16%
Enzyme Profile
100%
Finland
8%
First Year
8%
Glutamyl Transpeptidase
33%
Hepatitis Diagnosis
8%
Inflammatory Bowel Disease
100%
Infliximab
25%
Liver Biochemistry
8%
Liver Enzymes
100%
Metronidazole
8%
Pediatric Inflammatory Bowel Disease
16%
Primary Sclerosing Cholangitis
8%
Sex-specific
8%
Transaminase Elevations
50%
Treatment Episodes
16%
University of Helsinki
8%
Upper Normal Limit
8%
Ustekinumab
8%
Vedolizumab
8%
Medicine and Dentistry
Adalimumab
9%
Alanine Aminotransferase
100%
Autoimmune Hepatitis
36%
Disease Duration
9%
Elevated Transaminases
18%
Gamma-Glutamyl Transpeptidase
36%
Hexafluronium Bromide
9%
Inflammatory Bowel Disease
100%
Infliximab
27%
Liver Enzyme
100%
Metronidazole
9%
Odds Ratio
27%
Pediatrics
18%
Primary Sclerosing Cholangitis
9%
Ustekinumab
9%
Vedolizumab
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
9%
Alanine Aminotransferase
100%
Autoimmune Hepatitis
36%
Disease Duration
9%
Gamma Glutamyltransferase
36%
Hexafluronium Bromide
9%
Hypertransaminasemia
18%
Inflammatory Bowel Disease
100%
Infliximab
27%
Liver Enzyme
100%
Metronidazole
9%
Primary Sclerosing Cholangitis
9%
Ustekinumab
9%
Vedolizumab
9%
Immunology and Microbiology
Adalimumab
9%
Alanine
100%
Autoimmune Hepatitis
36%
Inflammatory Bowel Disease
100%
Infliximab
27%
Primary Sclerosing Cholangitis
9%
Ustekinumab
9%
Vedolizumab
9%